Studies how omeprazole and dextromethorphan are processed in young people with lymphoma
Tests whether drug processing changes in young people with Hodgkin or non-Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
Key facts
- Where
- Melbourne, AustraliaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, teenagers and young adults aged 6-25 years with a new diagnosis of Hodgkin or Non-Hodgkin lymphoma. They take probe medicines (omeprazole, dextromethorphan) and give blood samples.
- Age
- 6-25 years
- Sex
- All sexes can join.
- Disease stage
- New diagnosis of Hodgkin lymphoma or Non-Hodgkin lymphoma.
- Earlier treatment
- No previous cancer treatment (this must be the first cancer diagnosis).
Main reasons for not taking part
- Known allergy to omeprazole or dextromethorphan
- Grade IV organ dysfunction (liver, kidney or gut)
- Previous cancer treatment
- Unstable condition needing intensive care
- Cannot swallow or absorb the oral or tube-given medicines, or cannot give written consent
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 25 years old?
Source: NCT06383338, who can take part
Where in Australia
- Peter MacCallum Cancer CentreMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Murdoch Childrens Research Institute
- Trial code
- NCT06383338
- Record updated
- 27 August 2026
- Original description
PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers.Read full original descriptionShow less
A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.
PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers.
The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications.
The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.
Inclusion: Age 6-25 years of age; New diagnosis of Hodgkin Lymphoma or Non-Hodgkin Lymphoma; Able to swallow and absorb oral or nasogastric tube (NGT) administration of probe drugs; Able to provide written informed consent.
Exclusion: Has a known previous allergy to any of the probe medications (i.e., omeprazole or dextromethorphan); Had previous oncological treatment (not first cancer diagnosis); Any patient requiring urgent initiation of anti-cancer treatment outside hours where a member of the study staff is unable to approach the parent/guardian or participant for consent prior to commencing anti-cancer therapy will be ineligible for consent; Failure to comply with inclusion criteria; Common Terminology Criteria for Adverse Events (CTCAE) Grade IV end organ dysfunction (i.e., hepatic, renal, gastrointestinal); Is a clinically unstable patient requiring intensive care admission in high-risk circumstances will not be considered eligible for consent; Unable to provide written informed consent.